Omeros FY2025 EPS Estimate Raised by Cantor Fitzgerald

Omeros Co. (NASDAQ:OMER - Free Report) - Equities researchers at Cantor Fitzgerald boosted their FY2025 earnings estimates for Omeros in a report released on Monday, May 19th. Cantor Fitzgerald analyst O. Brayer now expects that the biopharmaceutical company will earn ($2.04) per share for the year, up from their prior forecast of ($2.19). The consensus estimate for Omeros' current full-year earnings is ($3.09) per share.

Omeros (NASDAQ:OMER - Get Free Report) last posted its quarterly earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.05).

Several other equities analysts also recently weighed in on the company. StockNews.com raised Omeros from a "sell" rating to a "hold" rating in a research report on Monday. Needham & Company LLC reissued a "hold" rating on shares of Omeros in a report on Friday, May 16th. Finally, D. Boral Capital restated a "buy" rating and issued a $36.00 target price on shares of Omeros in a report on Tuesday, May 13th. Three research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Omeros currently has a consensus rating of "Moderate Buy" and an average target price of $22.50.

Omeros Stock Down 0.9%

Shares of NASDAQ OMER opened at $3.29 on Wednesday. The firm has a market cap of $191.83 million, a price-to-earnings ratio of -1.42 and a beta of 2.42. Omeros has a 52-week low of $2.97 and a 52-week high of $13.60. The business's 50 day moving average is $6.88 and its two-hundred day moving average is $8.13.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Trexquant Investment LP acquired a new stake in shares of Omeros in the 1st quarter worth $88,000. Hsbc Holdings PLC acquired a new stake in Omeros during the first quarter worth about $142,000. Wellington Management Group LLP acquired a new stake in Omeros in the 1st quarter valued at $1,118,000. Nuveen LLC purchased a new position in Omeros in the 1st quarter worth approximately $938,000. Finally, Invesco Ltd. increased its stake in Omeros by 169.1% during the 1st quarter. Invesco Ltd. now owns 87,044 shares of the biopharmaceutical company's stock worth $716,000 after buying an additional 54,696 shares during the period. Institutional investors and hedge funds own 48.79% of the company's stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.